Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV(POS) Cancers

Immunotherapy for HPV(POS) malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including viral platforms such as VSV. A major advantage of VSV expressing th...

Descripción completa

Detalles Bibliográficos
Autores principales: Suksanpaisan, Lukkana, Xu, Rong, Tesfay, Mulu Z., Bomidi, Carolyn, Hamm, Stefan, Vandergaast, Rianna, Jenks, Nathan, Steele, Michael B., Ota-Setlik, Ayuko, Akhtar, Hinna, Luckay, Amara, Nowak, Rebecca, Peng, Kah Whye, Eldridge, John H., Clarke, David K., Russell, Stephen J., Diaz, Rosa Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037044/
https://www.ncbi.nlm.nih.gov/pubmed/29998190
http://dx.doi.org/10.1016/j.omto.2018.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037044/
https://www.ncbi.nlm.nih.gov/pubmed/29998190
http://dx.doi.org/10.1016/j.omto.2018.05.001

Ejemplares similares